INCB161734

Phase 3Small molecule

Incyte

INCB161734 is one of 69 small molecule programs targeting Solid Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Hepatic InsufficiencyNot yet recruiting

Renal InsufficiencyNot yet recruiting

Solid TumorPhase 3

Recruiting

Hepatic InsufficiencyPhase 1

Not yet recruiting

Renal InsufficiencyPhase 1

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

INCB161734

Incyte

Phase 3

2 2

Yervoy

Bristol-Myers Squibb

Preclinical

3 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 5

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 6

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 7

Interleukin 2

EEssen Biotech

Preclinical

2 8

IL-2

FFate Therapeutics

Preclinical

2 9

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

2 10

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Solid Tumor

NCT06179160

Phase 1Not yet recruiting

Renal Insufficiency

NCT07854249

Phase 1Not yet recruiting

Hepatic Insufficiency

NCT07853040

Q1 2029

Phase 3Recruiting

Solid Tumor

NCT07522073

Clinical

Trials by Indication[1]

Solid Tumor2 trials

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

Recruiting· Incyte logo

Incyte·Phase 3·NCT07522073·588 enrolled

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting· Incyte logo

Incyte·Phase 1·NCT06179160·710 enrolled

Oral1 trial

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Completed· Incyte logo

Incyte·Phase 1·NCT07018635·63 enrolled

Renal insufficiency1 trial

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis

Not yet recruiting· Incyte logo

Incyte·Phase 1·NCT07854249·24 enrolled

Hepatic Insufficiency1 trial

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment

Not yet recruiting· Incyte logo

Incyte·Phase 1·NCT07853040·24 enrolled

Unspecified1 trial

An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participants

Active, not recruiting· Incyte logo

Incyte·Phase 1·NCT07814404·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for INCB161734. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCB161734 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCB161734. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte

INCB161734

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2029

Trials by Indication[1]

Solid Tumor2 trials

Oral1 trial

Renal insufficiency1 trial

Hepatic Insufficiency1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News